GPC3 and hepatocellular carcinoma: Notably, when GPC3 is combined with AFP, AFP-L3%, or DCP, the complementary advantages among these markers achieve diagnostic performance comparable to AFP alone, significantly enhancing the ability to distinguish early HCC.